[Change of the LHRH analogue in progressive castration-refractory prostate cancer].

Heidenreich A, Porres D, Epplen R, van Erps T, Pfister D

Der Urologe. Ausg. A1 Sept 2012Cited by 2 (Europe PMC)

PMID22733398DOI10.1007/s00120-012-2948-9PepBankPUB-22733398

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In prostate cancer patients receiving salvage triptorelin, 25% achieved a PSA decrease of ≥50%.
In plain wordsIn prostate cancer patients, 25% had a PSA decrease of ≥50% during salvage triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePSA response
Study
n = 36
Outcome group
Tumor growth · Cancer
Studied dose
11.5 mg at 3-month intervalsAs given in this study (human).
Measurements
PSA decrease of at least 50%
25%
patients with PSA decrease of 50% or more
PSA decrease of at least 50%
9 patients
of 36 patients
Source sentences
Summary
A PSA decrease of ≥50% was reached in 9 out of 36 (25%) patients, 3 out of 36 (13.9%) patients each demonstrated stable PSA levels and a prolongation of PSADT from 6.2 to 9.8 months.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study 36 patients with prostate-specific antigen (PSA) progression following first line complete androgen blockade and antiandrogen (ADT) withdrawal were retrospectively analyzed.
Summary · context
All patients received TP at a dose of 11.5 mg at 3-month intervals until documented progression.
Report a problemFND-2273339801
02HumanObservational studyEfficacy outcome
In prostate cancer patients receiving salvage triptorelin, the abstract reports stable PSA in 3 out of 36 (13.9%) patients.
In plain wordsIn prostate cancer patients, the abstract reports stable PSA in 3 out of 36 patients during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStable PSA
Study
n = 36
Outcome group
Tumor growth · Cancer
Studied dose
11.5 mg at 3-month intervalsAs given in this study (human).
Measurements
Stable PSA
13.9%
patients with stable PSA as written in source
Stable PSA
3 patients
of 36 patients
Source sentences
Summary
A PSA decrease of ≥50% was reached in 9 out of 36 (25%) patients, 3 out of 36 (13.9%) patients each demonstrated stable PSA levels and a prolongation of PSADT from 6.2 to 9.8 months.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study 36 patients with prostate-specific antigen (PSA) progression following first line complete androgen blockade and antiandrogen (ADT) withdrawal were retrospectively analyzed.
Summary · context
All patients received TP at a dose of 11.5 mg at 3-month intervals until documented progression.
Report a problemFND-2273339802
03HumanObservational studyEfficacy outcome
In prostate cancer patients receiving salvage triptorelin, mean progression-free survival was 21.4 weeks.
In plain wordsIn prostate cancer patients receiving triptorelin, average survival without progression was 21.4 weeks.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableMean progression-free survival
Study
n = 36
Outcome group
Tumor growth · Cancer
Studied dose
11.5 mg at 3-month intervalsAs given in this study (human).
Measurements
Mean PFS
21.4 weeks
salvage triptorelin
Source sentences
Summary
Mean progression-free survival (PFS) was 21.4 weeks (7-53 weeks).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study 36 patients with prostate-specific antigen (PSA) progression following first line complete androgen blockade and antiandrogen (ADT) withdrawal were retrospectively analyzed.
Summary · context
All patients received TP at a dose of 11.5 mg at 3-month intervals until documented progression.
Report a problemFND-2273339804
04HumanObservational studyEfficacy outcome
In prostate cancer patients receiving salvage triptorelin, overall survival was 80.5% at a mean follow-up of 31.4 months.
In plain wordsIn prostate cancer patients receiving triptorelin, overall survival was 80.5% at the reported follow-up.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOverall survival
Study
n = 36
Outcome group
Mortality · Cancer
Studied dose
11.5 mg at 3-month intervalsAs given in this study (human).
Measurements
Overall survival
80.5%
salvage triptorelin
Source sentences
Summary
Mean follow-up was 31.4 months (27-39 months), overall survival was 80.5% and cancer-specific survival was 88.9%.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study 36 patients with prostate-specific antigen (PSA) progression following first line complete androgen blockade and antiandrogen (ADT) withdrawal were retrospectively analyzed.
Summary · context
All patients received TP at a dose of 11.5 mg at 3-month intervals until documented progression.
Report a problemFND-2273339805
05HumanObservational studyEfficacy outcome
In prostate cancer patients receiving salvage triptorelin, cancer-specific survival was 88.9% at a mean follow-up of 31.4 months.
In plain wordsIn prostate cancer patients receiving triptorelin, cancer-specific survival was 88.9% at the reported follow-up.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableCancer-specific survival
Study
n = 36
Outcome group
Mortality · Cancer
Studied dose
11.5 mg at 3-month intervalsAs given in this study (human).
Measurements
Cancer-specific survival
88.9%
salvage triptorelin
Source sentences
Summary
Mean follow-up was 31.4 months (27-39 months), overall survival was 80.5% and cancer-specific survival was 88.9%.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study 36 patients with prostate-specific antigen (PSA) progression following first line complete androgen blockade and antiandrogen (ADT) withdrawal were retrospectively analyzed.
Summary · context
All patients received TP at a dose of 11.5 mg at 3-month intervals until documented progression.
Report a problemFND-2273339806
06HumanObservational studyEfficacy outcome
In a subset receiving salvage triptorelin, PSA doubling time increased from 6.2 to 9.8 months.
In plain wordsIn a prostate cancer subset, PSA doubling time increased from 6.2 to 9.8 months during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePSA doubling time prolongation
Study
n = 3
Outcome group
Tumor growth · Cancer
Studied dose
11.5 mg at 3-month intervalsAs given in this study (human).
Measurements
PSA doubling time
6.2 months
start of reported prolongation
PSA doubling time
9.8 months
end of reported prolongation
Source sentences
Summary
A PSA decrease of ≥50% was reached in 9 out of 36 (25%) patients, 3 out of 36 (13.9%) patients each demonstrated stable PSA levels and a prolongation of PSADT from 6.2 to 9.8 months.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study 36 patients with prostate-specific antigen (PSA) progression following first line complete androgen blockade and antiandrogen (ADT) withdrawal were retrospectively analyzed.
Summary · context
All patients received TP at a dose of 11.5 mg at 3-month intervals until documented progression.
Report a problemFND-2273339803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.